-
2026-10-28
IND Approval: GenSci136 Advances into Sj?gren's SyndromeLearn More
-
2026-10-22
Phase 3 trial in China successfully confirms ACARIZAX? safety and efficacy in patients with house dust mite allergyLearn More
-
2026-10-10
GenSci's Oncology Innovation: NDA Approval Secured for Prostate CancerLearn More
-
2026-10-09
GenSci's Two Innovations Received IND Clearance from NMPALearn More
-
2026-09-03
GenSci Showcases Innovation at CPHI Korea 2026Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin? ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia?Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia? in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More